• Original article (Basic research) • Previous Articles     Next Articles

Preparation of VEGFR2-targeted PLGA ultrasound contrast agent and in vitro targeting tests

WANG Cui-wei1, DU Jing1, YANG Shi-ping2, HU He2, LI Feng-hua1   

  1. 1.Department of Ultrasound, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China; 2.Department of Chemistry, Shanghai Normal University, Shanghai 200234, China
  • Online:2014-06-28 Published:2014-06-30
  • Supported by:

    National Natural Science Foundation of China, 81102014


Objective To prepare the poly lactic-co-glycolic acid (PLGA) vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasound contrast agent and observe its targeting and imaging ability in vitro. Methods The PLGA nanoparticles (NPs) of macromolecule material were prepared by a modified double-emulsion solvent evaporation method. General properties of PLGA NPs were detected by the FE SEM. The contrast agent and anti-VEGFR2 antibody were conjugated to prepare the targeted ultrasound contrast agent by the carbodiimide method. The LSCM was used to evaluate the targeting ability in vitro and the high frequency ultrasonography was used to observe the imaging ability in vitro. Results NPs of PLGA ultrasound contrast agent were regularly round with uniform size and good dispersion. The PLGA VEGFR2-targeted ultrasound contrast agent firmly attached to the surface of SVEN1 ras (SVR) during the course of targeting tests in vitro. The in vitro ultrasound imaging of the PLGA VEGFR2-targeted ultrasound contrast agent showed fine punctuate hyper echo with no attenuation for the rear echo. Conclusion The PLGA VEGFR2-targeted ultrasound contrast agent is prepared successfully. It can specifically target and attach to SVR with high expression of VEGFR2 in vitro and its in vitro ultrasound imaging is good.

Key words: poly lactic-co-glycolic acid, nanoparticles, targeted ultrasound contrast agent, vascular endothelial growth factor receptor 2